Korsana Biosciences, Inc. - 8-K Filing

Korsana Biosciences reports Q3 2026 net loss of $46.4 million and announces completed merger with Cyclerion Therapeutics. (Items: 2.02 Results of Operations and Financial Condition, 9.01 Financial Statements and Exhibits)

SEC EDGAR ·

Tickers: $CYCN

Read the full article at SEC EDGAR

More Regulatory news